ABSTRACT
The use of the controlled human infection model to facilitate product development and to advance understanding of host-pathogen interactions is of increasing interest. While administering a virulent (or infective) organism to a susceptible host necessitates an ongoing evaluation of safety and ethical considerations, a central theme in conducting these studies in a safe and ethical manner that yields actionable data is their conduct in facilities well-suited to address their unique attributes. To that end, we have developed a framework for evaluating potential sites in which to conduct inpatient enteric controlled human infection model to ensure consistency and increase the likelihood of success.
Subject(s)
Host-Pathogen Interactions , Inpatients , HumansABSTRACT
BACKGROUND: No licensed cholera vaccine is presently available in the United States. Cholera vaccines available in other countries require 2 spaced doses. A single-dose cholera vaccine that can rapidly protect short-notice travelers to high-risk areas and help control explosive outbreaks where logistics render 2-dose immunization regimens impractical would be a major advance.PXVX0200, based on live attenuated Vibrio cholerae O1 classical Inaba vaccine strain CVD 103-HgR, elicits seroconversion of vibriocidal antibodies (a correlate of protection) within 10 days of a single oral dose. We investigated the protection conferred by this vaccine in a human cholera challenge model. METHODS: Consenting healthy adult volunteers, 18-45 years old, were randomly allocated 1:1 to receive 1 oral dose of vaccine (approximately 5 × 10(8) colony-forming units [CFU]) or placebo in double-blind fashion. Volunteers ingested approximately 1 × 10(5) CFU of wild-type V. cholerae O1 El Tor Inaba strain N16961 10 days or 3 months after vaccination and were observed on an inpatient research ward for stool output measurement and management of hydration. RESULTS: The vaccine was well tolerated, with no difference in adverse event frequency among 95 vaccinees vs 102 placebo recipients. The primary endpoint, moderate (≥3.0 L) to severe (≥5.0 L) diarrheal purge, occurred in 39 of 66 (59.1%) placebo controls but only 2 of 35 (5.7%) vaccinees at 10 days (vaccine efficacy, 90.3%; P < .0001) and 4 of 33 (12.1%) vaccinees at 3 months (vaccine efficacy, 79.5%; P < .0001). CONCLUSIONS: The significant vaccine efficacy documented 10 days and 3 months after 1 oral dose of PXVX0200 supports further development as a single-dose cholera vaccine. CLINICAL TRIALS REGISTRATION: NCT01895855.
Subject(s)
Antibodies, Bacterial/blood , Cholera Vaccines/administration & dosage , Cholera Vaccines/immunology , Cholera/prevention & control , Vibrio cholerae O1/immunology , Adolescent , Adult , Antibodies, Bacterial/immunology , Cholera/immunology , Cholera Vaccines/adverse effects , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
BACKGROUND: The 4 serotypes of dengue virus, DENV-1-4, are the leading cause of arboviral disease globally. The ideal dengue vaccine would provide protection against all serotypes after a single dose. METHODS: Two randomized, placebo-controlled trials were performed with 168 flavivirus-naive adults to demonstrate the safety and immunogenicity of a live attenuated tetravalent dengue vaccine (TV003), compared with those of a second tetravalent vaccine with an enhanced DENV-2 component (TV005), and to evaluate the benefit of a booster dose at 6 months. Safety data, viremia, and neutralizing antibody titers were evaluated. RESULTS: A single dose of TV005 elicited a tetravalent response in 90% of vaccinees by 3 months after vaccination and a trivalent response in 98%. Compared with TV003, the higher-dose DENV-2 component increased the observed frequency of immunogenicity to DENV-2 in the TV005 trial. Both the first and second doses were well tolerated. Neither vaccine viremia, rash, nor a significant antibody boost were observed following a second dose. CONCLUSIONS: A single subcutaneous dose of TV005 dengue vaccine is safe and induces a tetravalent antibody response at an unprecedented frequency among vaccinees. A second dose has limited benefit and appears to be unnecessary. Studies to confirm these findings and assess vaccine efficacy will now move to populations in regions where DENV transmission is endemic. CLINICAL TRIALS REGISTRATION: NCT01072786 and NCT01436422.
Subject(s)
Dengue Vaccines/immunology , Dengue Virus/immunology , Vaccination/methods , Adolescent , Adult , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Dengue Vaccines/administration & dosage , Dengue Vaccines/adverse effects , Drug-Related Side Effects and Adverse Reactions , Female , Healthy Volunteers , Humans , Injections, Subcutaneous , Male , Middle Aged , Placebos/administration & dosage , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/immunology , Viremia , Young AdultABSTRACT
BACKGROUND: Campylobacter jejuni is a common cause of diarrhea and is associated with serious postinfectious sequelae. Although symptomatic and asymptomatic infections are recognized, protective immunity is not well understood. Previous data suggests that interferon γ (IFN-γ) may be associated with protection. To better define the clinical and immunologic development of protective immunity to C. jejuni, we assessed the ability of an initial infection to prevent clinical illness after a second experimental infection. METHODS: Subjects with no clinical or immunologic evidence of prior infection with C. jejuni received an initial challenge with C. jejuni CG8421 with rechallenge 3 months later. The primary endpoint was campylobacteriosis, as defined by diarrhea and/or systemic signs. Close inpatient monitoring was performed. Serum immunoglobulin A (IgA) and immunoglobulin G (IgG), fecal IgA, IgA antibody-secreting cells (ASCs), and IFN-γ production were evaluated. All subjects were treated with antibiotics and were clinically well at discharge. RESULTS: Fifteen subjects underwent a primary infection with C. jejuni CG8421; 14 (93.3%) experienced campylobacteriosis. Eight subjects received the second challenge, and all experienced campylobacteriosis with similar severity. Immune responses after primary infection included serum IgA, IgG, ASC, and IFN-γ production. Responses were less robust after secondary infection. CONCLUSIONS: In naive healthy adults, a single infection with CG8421 did not protect against campylobacteriosis. Although protection has been demonstrated with other strains and after continuous environmental exposure, our work highlights the importance of prior immunity, repeated exposures, and strain differences in protective immunity to C. jejuni. CLINICAL TRIALS REGISTRATION: NCT01048112.
Subject(s)
Campylobacter Infections/immunology , Campylobacter jejuni/immunology , Adult , Campylobacter Infections/physiopathology , Campylobacter Infections/prevention & control , Diarrhea/immunology , Diarrhea/microbiology , Feces/chemistry , Female , Humans , Immunoglobulin A/analysis , Immunoglobulin A/blood , Immunoglobulin A/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Interferon-gamma/blood , Male , Young AdultABSTRACT
BACKGROUND: A robust human challenge model for Campylobacter jejuni is an important tool for the evaluation of candidate vaccines. The previously established model conveys a potential risk of Guillain-Barré syndrome attributable to lipooligosaccharide ganglioside mimicry. This work establishes a new C. jejuni human challenge model that uses a strain (CG8421) without ganglioside mimicry and that applies Campylobacter-specific cellular immunity screening to achieve high attack rates at lower inoculum doses. METHODS: Healthy Campylobacter-naive adults participated in an open-label challenge trial. Participants were dosed with C. jejuni CG8421 and followed as inpatients. Pattern of illness, bacterial shedding, and immunologic responses were determined. RESULTS: Following screening, 23 subjects received 1 X 10(6) or 1 X 10(5) colony-forming units of C. jejuni, with attack rates (percentage of patients who became ill) of 100% (1 X 10(6) colony-forming units) or 93% (1 X 10(5) colony-forming units). Every subject shed CG8421; the median time to diarrhea onset was 72.3 h (interquartile range, 53.9-99.9 h). Symptoms included abdominal cramps (74%), nausea (65%), and fever (39%). No major safety concerns occurred, including bacteremia, hypotension, or postinfectious sequelae. Unexpectedly, recrudescent infection occurred in 2 subjects (1 subject without Campylobacter-specific adaptive immune responses and 1 with azithromycin resistance acquired in vivo); both infections cleared after receipt of additional antibiotics. Cumulative Campylobacter-specific immune responses were as follows: serologic response occurred in 87% (immunoglobulin [Ig] A) and 48% (IgG) of subjects, in vitro interferon-gamma production occurred in 91% of subjects, and 96% of subjects had IgA antibody-secreting cells and fecal IgA detected. CONCLUSIONS: The C. jejuni CG8421 challenge model provides a safe and effective tool, without the risk of Guillain-Barré syndrome. The model demonstrates high attack rates after lower doses of challenge inoculum, provides further understanding of immunologic responses, and permits future investigation of candidate Campylobacter vaccines.
Subject(s)
Bacterial Vaccines/immunology , Campylobacter Infections/microbiology , Campylobacter Infections/pathology , Campylobacter jejuni/immunology , Campylobacter jejuni/pathogenicity , Drug Evaluation/methods , Adolescent , Adult , Antibodies, Bacterial/blood , Campylobacter Infections/immunology , Campylobacter Infections/prevention & control , Diarrhea/immunology , Diarrhea/microbiology , Diarrhea/pathology , Feces/chemistry , Feces/microbiology , Female , Human Experimentation , Humans , Immunoglobulin A/analysis , Immunoglobulin G/blood , Interferon-gamma/metabolism , Leukocytes, Mononuclear/immunology , Male , Middle Aged , Young AdultABSTRACT
BACKGROUND: Antibodies targeting O-specific polysaccharide (OSP) of Vibrio cholerae may protect against cholera; however, little is known about this immune response in infected immunologically naïve humans. METHODOLOGY: We measured serum anti-OSP antibodies in adult North American volunteers experimentally infected with V. cholerae O1 Inaba El Tor N16961. We also measured vibriocidal and anti-cholera toxin B subunit (CtxB) antibodies and compared responses to those in matched cholera patients in Dhaka, Bangladesh, an area endemic for cholera. PRINCIPAL FINDINGS: We found prominent anti-OSP antibody responses following initial cholera infection: these responses were largely IgM and IgA, and highest to infecting serotype with significant cross-serotype reactivity. The anti-OSP responses peaked 10 days after infection and remained elevated over baseline for ≥ 6 months, correlated with vibriocidal responses, and may have been blunted in blood group O individuals (IgA anti-OSP). We found significant differences in immune responses between naïve and endemic zone cohorts, presumably reflecting previous exposure in the latter. CONCLUSIONS: Our results define immune responses to O-specific polysaccharide in immunologically naive humans with cholera, find that they are largely IgM and IgA, may be blunted in blood group O individuals, and differ in a number of significant ways from responses in previously humans. These differences may explain in part varying degrees of protective efficacy afforded by cholera vaccination between these two populations. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT01895855.
Subject(s)
Antibodies, Bacterial/blood , Cholera/immunology , Cholera/microbiology , Immunity, Humoral , O Antigens/immunology , Vibrio cholerae O1/immunology , Vibrio cholerae O1/isolation & purification , Adolescent , Adult , Antitoxins/blood , Bangladesh , Cholera Toxin/immunology , Female , Humans , Immunoglobulin A/blood , Immunoglobulin M/blood , Male , Middle Aged , North America , Young AdultABSTRACT
BACKGROUND: The single-dose live attenuated vaccine CVD 103-HgR protects against experimental Vibrio cholerae infection in cholera-naïve adults for at least 6â¯months after vaccination. While vaccine-induced vibriocidal seroconversion is associated with protection, vibriocidal titers decline rapidly from their peak 1-2â¯weeks after vaccination. Although vaccine-induced memory B cells (MBCs) might mediate sustained protection in individuals without detectable circulating antibodies, it is unknown whether oral cholera vaccination induces a MBC response. METHODS: In a study that enrolled North American adults, we measured lipopolysaccharide (LPS)- and cholera toxin (CtxB)-specific MBC responses to PXVX0200 (derived from the CVD 103-HgR strain) and assessed stool volumes following experimental Vibrio cholerae infection. We then evaluated the association between vaccine-induced MBC responses and protection against cholera. RESULTS: There was a significant increase in % CT-specific IgG, % LPS-specific IgG, and % LPS-specific IgA MBCs which persisted 180â¯days after vaccination as well as a significant association between vaccine-induced increase in % LPS-specific IgA MBCs and lower post-challenge stool volume (râ¯=â¯-0.56, pâ¯<â¯0.001). DISCUSSION: Oral cholera vaccination induces antigen-specific MBC responses, and the anamnestic LPS-specific responses may contribute to long-term protection and provide correlates of the duration of vaccine-induced protection. CLINICAL TRIALS REGISTRATION: NCT01895855.
Subject(s)
B-Lymphocytes/immunology , Cholera Vaccines/immunology , Cholera/prevention & control , Immunologic Memory , Lipopolysaccharides/immunology , Vibrio cholerae O1/immunology , Administration, Oral , Adult , Antibodies, Bacterial/blood , Cholera Toxin/immunology , Cholera Vaccines/administration & dosage , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Time Factors , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunologyABSTRACT
BACKGROUND: Cholera is an acute voluminous dehydrating diarrheal disease caused by toxigenic strains of Vibrio cholerae O1 and occasionally O139. A growing body of evidence indicates that immune responses targeting the O-specific polysaccharide (OSP) of V. cholerae are involved in mediating protection against cholera. We therefore assessed whether antibody responses against OSP occur after vaccination with live attenuated oral cholera vaccine CVD 103-HgR, and whether such responses correlate with protection against cholera. METHODOLOGY: We assessed adult North American volunteers (n = 46) who were vaccinated with 5 × 108 colony-forming units (CFU) of oral cholera vaccine CVD 103-HgR and then orally challenged with approximately 1 × 105 CFU of wild-type V. cholerae O1 El Tor Inaba strain N16961, either 10 or 90 days post-vaccination. PRINCIPAL FINDINGS: Vaccination was associated with induction of significant serum IgM and IgA anti-OSP and vibriocidal antibody responses within 10 days of vaccination. There was significant correlation between anti-OSP and vibriocidal antibody responses. IgM and IgA anti-OSP responses on day 10 following vaccination were associated with lower post-challenge stool volume (r = -0.44, P = 0.002; r = -0.36, P = 0.01; respectively), and none of 27 vaccinees who developed a ≥1.5 fold increase in any antibody isotype targeting OSP on day 10 following vaccination compared to baseline developed moderate or severe cholera following experimental challenge, while 5 of 19 who did not develop such anti-OSP responses did (P = 0.01). CONCLUSION: Oral vaccination with live attenuated cholera vaccine CVD 103-HgR induces antibodies that target V. cholerae OSP, and these anti-OSP responses correlate with protection against diarrhea following experimental challenge with V. cholerae O1. TRIAL REGISTRATION: ClinicalTrials.gov NCT01895855.
Subject(s)
Antibodies, Bacterial/blood , Cholera Vaccines/administration & dosage , Cholera Vaccines/immunology , Cholera/prevention & control , O Antigens/immunology , Administration, Oral , Adult , Antibody Formation , Cholera/immunology , Double-Blind Method , Female , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , United States , Vaccination/methods , Vibrio cholerae O1/immunology , VolunteersABSTRACT
BACKGROUND: Symptom-limited treadmill testing is commonly performed on entry to cardiac rehabilitation (CR) for its prognostic value and to design a safe and effective exercise program. Normative values for this evaluation are not available. The primary goals of this study were to establish normative values for peak aerobic capacity (peak V(O2)) for patients entering CR and to create nomograms for conversion of peak V(O2) to a percentage of predicted exercise capacity,stratified by age, gender, and diagnosis. METHODS AND RESULTS: Peak V(O2) was measured in 2896 patients entering CR from 1996 to 2004. Peak V(O2) was higher in men than in women: 19.3 +/- 6.1 mL.kg(-1).min(-1) (range, 5.2 to 49.7 mL.kg(-1).min(-1)) versus 14.5 +/- 3.9 mL.kg(-1).min(-1) (range, 3.8 to 29.8 mL.kg(-1).min(-1)) (P < 0.0001). Peak V(O2) decreased steadily with age with a greater rate of decline in men than women (0.242 versus 0.116 mL.kg(-1).min(-1) per year) (P < 0.01). Factors associated with lower peak V(O2) include coronary artery bypass grafting (CABG), angina at stress testing, hypertension,and, in women, beta-blocking medications. Nomograms are presented for individual values to be compared with mean values by age, gender, and cardiac diagnosis. These include a nomogram to convert estimated maximal metabolic equivalents to actual peak V(O2) for patients who do not undergo direct measurement of peak V(O2). CONCLUSIONS: Values of peak V(O2) on entry to CR are extremely low, particularly in women, approaching values seen with severe chronic heart failure. This underscores the importance of CR after a major cardiac event to improve physical function and long-term prognosis.
Subject(s)
Exercise Test , Exercise , Heart Diseases/rehabilitation , Nomograms , Adrenergic beta-Antagonists/adverse effects , Adrenergic beta-Antagonists/therapeutic use , Adult , Age Factors , Aged , Aged, 80 and over , Angina Pectoris/complications , Angina Pectoris/physiopathology , Antihypertensive Agents/adverse effects , Antihypertensive Agents/therapeutic use , Breath Tests , Coronary Artery Bypass , Diabetes Complications/physiopathology , Diagnosis-Related Groups , Female , Heart Diseases/classification , Heart Diseases/complications , Heart Diseases/physiopathology , Humans , Hypertension/complications , Hypertension/drug therapy , Hypertension/physiopathology , Male , Middle Aged , Obesity/complications , Obesity/physiopathology , Oxygen Consumption , Postoperative Period , Racial Groups , Rehabilitation Centers , Sex Factors , SmokingABSTRACT
One potential advantage of live attenuated bacterial vaccines is the ability to stimulate responses to antigens which are only expressed during the course of infection. To determine whether the live attenuated cholera vaccine CVD 103-HgR (Vaxchora) results in antibody responses to the in vivo-induced toxin-coregulated pilus antigen TcpA, we measured IgA and IgG responses to Vibrio cholerae O1 El Tor TcpA in a subset of participants in a recently reported experimental challenge study. Participants were challenged with V. cholerae O1 El Tor Inaba N16961 either 10 days or 90 days after receiving the vaccine or a placebo. Neither vaccination nor experimental infection with V. cholerae alone resulted in a robust TcpA IgG or IgA response, but each did elicit a strong response to cholera toxin. However, compared to placebo recipients, vaccinees had a marked increase in IgG TcpA antibodies following the 90-day challenge, suggesting that vaccination with CVD 103-HgR resulted in priming for a subsequent response to TcpA. No such difference between vaccine and placebo recipients was observed for volunteers challenged 10 days after vaccination, indicating that this was insufficient time for vaccine-induced priming of the TcpA response. The priming of the response to TcpA and potentially other antigens expressed in vivo by attenuated V. cholerae may have relevance to the maintenance of immunity in areas where cholera is endemic.
Subject(s)
Antibodies, Bacterial/blood , Cholera Vaccines/administration & dosage , Cholera Vaccines/immunology , Cholera/prevention & control , Fimbriae Proteins/immunology , Vibrio cholerae O1/immunology , Adult , Antigens, Bacterial/immunology , Cholera/immunology , Double-Blind Method , Female , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Male , Placebos/administration & dosage , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunology , VolunteersABSTRACT
PURPOSE: This study aimed to assess the clinical outcomes and adverse events among patients with implantable cardiac defibrillators (ICDs) in cardiac rehabilitation programs. METHODS: Data were compared for 42 consecutive patients with ICDs and 42 control patients matched by age, gender, and left ventricular ejection fraction without ICDs and enrolled in the same program. RESULTS: The number of cardiac rehabilitation exercise sessions for each group was 828 and 925, respectively. Only 1 patient experienced an ICD firing during exercise; there were no cardiac arrests and no deaths in either group. Compliance with cardiac rehabilitation was similar in both groups with most dropouts for nonmedical reasons and similar rates for cardiac-related reasons. Improvements in exercise capacity were similar between groups (30% in ICD patients and 37% in controls). CONCLUSIONS: Although larger studies are needed, these data suggest that supervised exercise training in patients with ICDs appears to be safe and effective.